The present disclosure is directed to compositions for the promotion of muscle protein synthesis and control of tumor-induced weight loss in patients that are, for example, suffering from cancer cachexia. The present disclosure is also directed to methods of administering such compositions.
대표청구항▼
1. A composition comprising: leucine, valine in an amount of about 8% to about 10% by weight based on the weight of total amino acids, and at least one essential amino acid in an amount of at least about 15 g in free form per dose, the essential amino acid selected from the group consisting of isole
1. A composition comprising: leucine, valine in an amount of about 8% to about 10% by weight based on the weight of total amino acids, and at least one essential amino acid in an amount of at least about 15 g in free form per dose, the essential amino acid selected from the group consisting of isoleucine, lysine, methionine, phenylalanine, threonine, tryptophan, histidine, and combinations thereof in free form, the leucine, in free form, being present in an amount of at least 30% to about 95% by weight based on the weight of total amino acids and a ratio of total essential amino acids to total amino acids ranging from about 0.60 to about 0.90. 2. A composition comprising: leucine, valine in an amount of about 8% to about 10% by weight based on the weight of total amino acids, and at least one essential amino acid in an amount of at least about 15 g in free form per dose, the essential amino acid selected from the group consisting of isoleucine, lysine, methionine, phenylalanine, threonine, tryptophan, histidine, and combinations thereof in free form, total leucine being present in an amount of at least 30% to about 35% by weight based on the weight of total amino acids and a ratio of total essential amino acids to total amino acids ranging from about 0.60 to about 0.90. 3. A composition comprising: a) leucine, valine in an amount of about 8% to about 10% by weight based on the weight of total amino acids, and at least one essential amino acid in an amount of at least about 15 g in free form per dose, the essential amino acid selected from the group consisting of isoleucine, lysine, methionine, phenylalanine, threonine, tryptophan, histidine, and combinations thereof and, optionally, at least one conditionally essential amino acid selected from the group consisting of tyrosine, cysteine, arginine, glutamine, and combinations thereof in free form, andb) at least one intact protein selected from the group consisting of casein, whey protein, soy protein, collagen, wheat protein, and combinations thereof, a ratio of total essential amino acids and, optionally, conditionally essential amino acids to total amino acids ranging from about 0.60 to about 0.90 and the leucine, in free form, being present in an amount of at least 30% by weight based on the weight of intact protein, and the ratio of leucine in free form to leucine in form of the intact protein being about 3:1 to about 1:3. 4. The composition of claim 3, wherein the essential amino acid is at least two selected from the group consisting of isoleucine, lysine, methionine, phenylalanine, threonine, tryptophan, or histidine. 5. The composition of claim 3, further comprising methionine in free form in an amount of at least about 0.5% to about 5% by weight based on the weight of total amino acids. 6. The composition of claim 3, further comprising an n−3 polyunsaturated fatty acid. 7. The composition of claim 6, wherein the n−3 polyunsaturated fatty acid is selected from the group consisting of u-linolenic acid, eicosapentaenoic acid, docosahexaenoic acid, and combinations thereof. 8. The composition of claim 3, further comprising at least about 1 g of eicosapentaenoic acid per serving or at least about 2 g of eicosapentaenoic acid per dose. 9. The composition of claim 3, further comprising tocopherol. 10. The composition of claim 9, wherein the tocopherol is present in an amount about 50 mg per serving or at least 150 mg per dose. 11. The composition of claim 3, comprising from about 15 g to about 55 g of the essential amino acids in free form per dose. 12. The composition of claim 3, comprising from about 12 g to about 15 g leucine in free form per dose. 13. The composition of claim 3, further comprising methionine in free form in an amount of at least about 5% to about 7% by weight based on the weight of total amino acids. 14. A kit comprising: a) a first composition comprising:1) leucine, valine in an amount of about 8% to about 10% by weight based on the weight of total amino acids, and at least one essential amino acid in an amount of at least about 15 g in free form per dose, the essential amino acid selected from the group consisting of isoleucine, lysine, methionine, phenylalanine, threonine, tryptophan, histidine, and combinations thereof and, optionally, at least one conditionally essential amino acid selected from the group consisting of tyrosine, cysteine, arginine and glutamine in free form, and2) at least one intact protein selected from the group consisting of casein, whey protein, soy protein, collagen, wheat protein, and combinations thereof, a ratio of total essential amino acids and, optionally, conditionally essential amino acids to total amino acids ranging from about 0.60 to about 0.90 and the leucine, in free form, being present in an amount of at least 30% by weight based on the weight of intact protein, and the ratio of leucine in free form to leucine in form of the intact protein being about 3:1 to about 1:3; andb) a second composition comprising an anti-cancer drug, the anticancer drug being selected from the group consisting of 5-fluorouracil, mitomycin-C, adriamycin, chloroethyl nitrosureas, methotrexate, and combinations thereof. 15. A composition consisting essentially of: leucine, valine in an amount of about 8% to about 10% by weight based on the weight of total amino acids, and at least one essential amino acid in an amount of at least about 15 g in free form per dose, the essential amino acid selected from the group consisting of isoleucine, lysine, methionine, phenylalanine, threonine, tryptophan, histidine, and combinations thereof in free form, and leucine, in free form, being present in an amount of at least 30% by weight based on the weight of total amino acids. 16. A composition consisting essentially of: leucine, valine in an amount of about 8% to about 10% by weight based on the weight of total amino acids, and at least one essential amino acid in an amount of at least about 15 g in free form per dose, the essential amino acid selected from the group consisting of isoleucine, lysine, methionine, phenylalanine, threonine, tryptophan, histidine, and combinations thereof in free form, and total leucine being present in an amount of at least 30% by weight based on the weight of total amino acids. 17. A composition consisting essentially of: a) leucine, valine in an amount of about 8% to about 10% by weight based on the weight of total amino acids, and at least one essential amino acid in an amount of at least about 15 g in free form per dose, the essential amino acid selected from the group consisting of isoleucine, lysine, methionine, phenylalanine, threonine, tryptophan, histidine, and combinations thereof and, optionally, at least one conditionally essential amino acid selected from the group consisting of tyrosine, cysteine, arginine, glutamine, and combinations thereof in free form, and the leucine, in free form, being present in an amount of at least 30%, andb) at least one intact protein selected from the group consisting of casein, whey protein, soy protein, collagen, wheat protein, and combinations thereof, a ratio of total essential amino acids and, optionally, conditionally essential amino acids, to total amino acids ranging from about 0.60 to about 0.90, and the ratio of leucine in free form to leucine in form of the intact protein being about 3:1 to about 1:3. 18. A kit comprising: a) a first composition consisting essentially of:1) leucine, valine in an amount of about 8% to about 10% by weight based on the weight of total amino acids, and at least one essential amino acid in an amount of at least about 15 g in free form per dose, the essential amino acid selected from the group consisting of isoleucine, lysine, methionine, phenylalanine, threonine, tryptophan, histidine, and combinations thereof, and, optionally, at least one conditionally essential amino acid selected from the group consisting of tyrosine, cysteine, arginine, glutamine, and combinations thereof, in free form, and the leucine, in free form, being present in an amount of at least 30%, and2) at least one intact protein selected from the group consisting of casein, whey protein, soy protein, collagen, wheat protein, and combinations thereof, a ratio of total essential amino acids and, optionally, conditionally essential amino acids to total amino acids ranging from about 0.60 to about 0.90, and the ratio of leucine in free form to leucine in form of the intact protein being about 3:1 to about 1:3; andb) a second composition comprising an anti-cancer drug, the anticancer drug being selected from the group consisting of 5-fluorouracil, mitomycin-C, adriamycin, chloroethyl nitrosureas, methotrexate, and combinations thereof.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (20)
Heyland, Sven; Fournet, Gaston; Bosch, Hans, Cheese flavoring product.
Cope Frederick Oliver (Worthington OH) Rausch Linda Sue (Blacklick OH) Richards Ernest William (Columbus OH) Smith Michelle Marie (Westerville OH) Abbruzzese Bonnie Chandler (Dublin OH) Pero Joan Mar, Enteral nutritional product.
Cope Frederick O. (Worthington OH) DeWille Normanella T. (Upper Arlington OH) Richards Ernest W. (Columbus OH) Mazer Terrence B. (Reynoldsburg OH) Abbruzzese Bonnie C. (Dublin OH) Snowden Gregory A. , Enteral nutritional product for patients undergoing radiation therapy and/or chemotherapy.
Salvati, Mark E.; Mitt, Toomas; Patel, Ramesh N.; Hanson, Ronald L.; Brzozowski, David; Goswami, Animesh; Chu, Linda Nga Hoong; Li, Wen-sen; Simpson, James H.; Totleben, Michael J.; He, Weixuan, Method for the preparation of fused heterocyclic succinimide compounds and analogs thereof.
Abbruzzese Bonnie Chandler ; McCamish Mark Anthony ; Cope Frederick Oliver ; Demichele Stephen Joseph, Method for the prevention and treatment of cachexia and anorexia.
Abbruzzese Bonnie Chandler ; McCamish Mark Anthony ; Cope Frederick Oliver ; Demichele Stephen Joseph, Method for the prevention and treatment of cachexia and anorexia.
Bonnie Chandler Abbruzzese ; Mark Anthony McCamish ; Frederick Oliver Cope ; Stephen Joseph DeMichele, Method for the prevention and treatment of cachexia and anorexia.
Cope Frederick O. (Worthington OH) DeWille Normanella T. (Upper Arlington OH) Richards Ernest W. (Columbus OH) Mazer Terrence B. (Reynoldsburg OH) Abbruzzese Bonnie C. (Dublin OH) Snowden Gregory A. , Method of providing enteral nutritional support for patients undergoing radiation therapy and/or chemotherapy.
Robert Johan Joseph Hageman NL; Rudolf Leonardus Lodewijk Smeets NL; George Verlaan NL, Nutritional preparation comprising ribose and medical use thereof.
Bistrian Bruce R. (Ipswich MA) Babayan Vigen R. (Waban MA) Blackburn George L. (Jamaica Plain MA), Nutritional supplement for treatment of cancer cachexia.
Cerra Frank B. (4522 Arden Ave. S.E. Edina MN 55424) Amen Ronald J. (18101 Catherine Cir. Villa Park CA 92667), Preparation for the prevention of catabolism.
Yoshimura Norman N. (Westminster CA) Barbul Adrian (Baltimore MD) Tao Robert C. (Huntington Beach CA) Storm Michael C. (Laguna Niguel CA) Kelley Robert E. (Orange CA) Reis Brenda L. (Costa Mesa CA), Use of arginine as an immunostimulator.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.